Dr. Dixon on Systemic Advances in Breast Cancer

J. Michael Dixon, MD
Published: Tuesday, Sep 13, 2011

J. Michael Dixon, MBChB, MD, Professor of Surgery and Consultant Surgeon of the University of Edinburgh; and Clinical Director of the Edinburgh Breast Unit at the Western General Hospital in Edinburgh, Scotland, describes all of the recent advances in breast cancer systemic therapy.

Dixon explains that in the hormonal systemic therapy there has been an advance in the treatment of postmenopausal women using aromatase inhibitors.

Chemotherapy and targeted agents have advanced considerably with the increased use of taxane drugs, anthracyclines, and anti-HER2 drugs such lapatinib and pertuzumab.
 
J. Michael Dixon, MBChB, MD, Professor of Surgery and Consultant Surgeon of the University of Edinburgh; and Clinical Director of the Edinburgh Breast Unit at the Western General Hospital in Edinburgh, Scotland, describes all of the recent advances in breast cancer systemic therapy.

Dixon explains that in the hormonal systemic therapy there has been an advance in the treatment of postmenopausal women using aromatase inhibitors.

Chemotherapy and targeted agents have advanced considerably with the increased use of taxane drugs, anthracyclines, and anti-HER2 drugs such lapatinib and pertuzumab.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x